학술논문

877PFirst-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial.
Document Type
Article
Source
Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. 1 Chart.
Subject
*RENAL cell carcinoma
Language
ISSN
0923-7534